Benchmark has downgraded Exact Sciences Corp (EXAS) to a Hold rating from Buy, effective November 23, 2025. The stock is currently priced at $101.01.
This downgrade underscores a shift in sentiment regarding the company's outlook, potentially reflecting rising competitive pressures, challenging market conditions, or execution risks that could affect performance.
Exact Sciences, headquartered in Madison, Wisconsin, is a prominent player in the biotechnology sector, focusing on cancer screening and diagnostics. The company employs approximately 6,900 individuals and operates a portfolio of products aimed at early cancer detection and treatment guidance. Its flagship offering, the Cologuard test, is a non-invasive screening tool for colorectal cancer, utilizing a multi-target approach to identify DNA and hemoglobin biomarkers associated with the disease.
The recent downgrade follows a series of analyst actions affecting Exact Sciences. Notably, Jefferies also downgraded the stock to Hold from Buy on the same day, while William Blair, Wells Fargo, and Guggenheim made similar adjustments in the preceding days.
Analyst ratings provide valuable insights but should be considered alongside other factors such as company fundamentals, competitive positioning, and industry trends. As of November 1, 2025, the consensus rating for Exact Sciences remains a Buy, with 12 analysts rating it as Strong Buy, 14 as Buy, and 4 as Hold.
Exact Sciences is set to report its upcoming earnings on August 4, 2026, with an estimated EPS of $0.12 and revenue of $935.7 million. The company has faced volatility in earnings, with its most recent report for Q3 2025 showing an EPS of -$0.10, which was below the expected -$0.07.
As the landscape evolves, the company's strategic focus on colorectal cancer screening, multi-cancer early detection (MCED), and minimal residual disease (MRD) test development will be critical to its future performance.